These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8777174)

  • 1. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
    André T; Lotz JP; Bouleuc C; Azzouzi K; Houry S; Hannoun L; See J; Esteso A; Avenin D; Izrael V
    Ann Oncol; 1996 Feb; 7(2):173-8. PubMed ID: 8777174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
    Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer.
    Huguier M; Barrier A; Valinas R; Flahault A; Adloff M; Pezet D; Jaeck D; Millat B;
    Hepatogastroenterology; 2001; 48(39):875-8. PubMed ID: 11462946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
    Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
    Sporn JR; Buzaid AC; Slater D; Cohen N; Greenberg BR
    Am J Clin Oncol; 1997 Feb; 20(1):81-3. PubMed ID: 9020295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.
    Todd KE; Gloor B; Lane JS; Isacoff WH; Reber HA
    J Gastrointest Surg; 1998; 2(2):159-66. PubMed ID: 9834413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
    Ducreux M; Rougier P; Pignon JP; Douillard JY; Seitz JF; Bugat R; Bosset JF; Merouche Y; Raoul JL; Ychou M; Adenis A; Berthault-Cvitkovic F; Luboinski M;
    Ann Oncol; 2002 Aug; 13(8):1185-91. PubMed ID: 12181240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
    Nicolson M; Webb A; Cunningham D; Norman A; O'Brien M; Hill A; Hickish T
    Ann Oncol; 1995 Oct; 6(8):801-4. PubMed ID: 8589018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
    Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.